Nuvation Bio Inc.

Nuvation Bio Inc. is a clinical‑stage biopharma headquartered in New York. It leads oncology therapeutics—taletrectinib for ROS1+ NSCLC, Safusidenib in phase 2 for mutant IDH1, and a novel NUV‑868 BET inhibitor—offering a diversified pipeline poised for growth.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 291
HQ: New York

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
NUVB	Nuvation Bio Inc. Cap: 2.8B	EQUITY	NYQ	USD	US67080N1019	Active	📈